RFK Jr., an investor in a CRISPR biotech, has raised alarms about the technology – STAT

Complete your personal information for a more tailored experience
Home
Don't miss out
Subscribe to STAT+ today, for the best life sciences journalism in the industry
By Jonathan Wosen
Jan. 22, 2025
West Coast Biotech & Life Sciences Reporter
Robert F. Kennedy Jr.’s disclosure on Wednesday that he invested in a gene-editing biotech belies a yearslong track record of voicing concerns about a technology he would be in position to regulate if confirmed to lead the federal health department.
On multiple occasions, Kennedy has commented on the potential of CRISPR, a potent and powerful gene-editing tool, to disrupt DNA in unintended and unsafe ways. The nonprofit that RFK Jr. founded and led for years, Children’s Health Defense, has repeatedly raised those same concerns. That track record raises the question of how he would regulate gene-editing research and drug development as head of the Department of Health and Human Services, a role that would give him power over the Food and Drug Administration and the National Institutes of Health, among other agencies.
advertisement
Experts in the field noted that Kennedy’s past comments reflect longstanding concerns about the safety of gene editing that researchers themselves have flagged, but which haven’t been borne out by data from drugs that are moving through clinical trials and beginning to reach patients as approved therapies.
STAT+ Exclusive Story
Already have an account? Log in
Already have an account? Log in
Monthly
$39
Totals $468 per year
Totals $468 per year
Starter
$30
for 3 months, then $399/year
Then $399/year
Annual
$399
Save 15%
Save 15%
11+ Users
Custom
Savings start at 25%!
Savings start at 25%!
2-10 Users
$300
Annually per user
$300 Annually per user
To read the rest of this story subscribe to STAT+.
Jonathan Wosen
West Coast Biotech & Life Sciences Reporter
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter.
Your morning rundown of the science, politics, and money driving biotech today
Your data will be processed in accordance with our Privacy Policy and Terms of Service. You may opt out of receiving STAT communications at any time.
By Sarah Owermohle, Isabella Cueto, and Rachel Cohrs Zhang
By Elaine Chen
advertisement
By Angus Chen
By Meghana Keshavan
By Allison DeAngelis
By Brittany Trang
By Allison DeAngelis
By Angus Chen
By Allison DeAngelis
By Lizzy Lawrence
Share options
X
Bluesky
LinkedIn
Facebook
Doximity
Copy link
Reprints
Reporting from the frontiers of health and medicine
Company
Account
More

source

Leave a Comment

Your email address will not be published. Required fields are marked *